Ipamorelin: Research, Mechanism & Current Evidence

What is Ipamorelin?

Ipamorelin is a synthetic peptide of five amino acids that acts on the ghrelin receptor. Ghrelin is the hormone best known for stimulating appetite, but the same receptor also triggers growth hormone release from the pituitary gland.

It was originally developed by Novo Nordisk under the code NNC 26-0161 and studied for post-operative gut function. It was not brought to market.

Status: Not an approved medicine. Prohibited in sport by WADA.

What is Ipamorelin researched for?

The defining research question is selectivity: whether growth hormone can be stimulated without also raising cortisol, prolactin and appetite, which earlier compounds in the same family did.

Other studied areas include gastrointestinal motility after surgery and bone density in animal models.

• Consistent GH elevation 30-60 minutes post-injection, maintaining natural pulsatile patterns.
• Increases insulin-like growth factor-1 through natural GH pathways.
• Supports cellular regeneration, collagen synthesis, and tissue repair.
• Promotes muscle growth and maintenance through GH-mediated pathways.
• Enhances lipolysis and metabolic rate through natural GH elevation.
• Improved sleep latency and increased slow-wave sleep duration.
• Enhanced recovery markers and reduced soreness after training.

How does Ipamorelin work?

Rather than supplying growth hormone directly, ipamorelin prompts the pituitary to release its own. This preserves the body's natural pulsed release pattern and the feedback loops that limit it.

The technical description is that it is a selective agonist at the growth hormone secretagogue receptor GHS-R1a.

Reported targets: ghrelin receptor

What does the research show?

Preclinical and early clinical pharmacology studies established that it raises growth hormone with less effect on cortisol and prolactin than GHRP-6 or GHRP-2.

A clinical programme for post-operative ileus did not demonstrate enough benefit to continue development.

Limitations of the current evidence

Development was discontinued, so there is no long-term human safety or efficacy data.

Most claims about body composition come from extrapolating growth hormone physiology rather than from trials of ipamorelin itself.

References

1. Ipamorelin, the first selective growth hormone secretagogue

   Raun K, Hansen BS, Johansen NL, et al. · European journal of endocrinology · 1998

   Identified ipamorelin as the first GHRP-receptor agonist with selectivity for GH release similar to GHRH. Did not release ACTH or cortisol at doses over 200-fold higher than the ED50 for GH release, distinguishing it from other secretagogues.

   PMID 9849822

2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

   Gobburu JV, Agersø H, Jusko WJ, et al. · Pharmaceutical research · 1999

   Dose-escalation study in 40 healthy males established terminal half-life of 2 hours, clearance of 0.078 L/h/kg. Ipamorelin induced single-episode GH release peaking at 0.67 hours with dose-proportional pharmacokinetics.

   PMID 10496658

3. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

   Johansen PB, Nowak J, Skjaerbaek C, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999

   Ipamorelin dose-dependently increased longitudinal bone growth rate from 42 to 52 mcm/day and produced pronounced dose-dependent body weight gain in adult female rats over 15 days.

   Animal study · PMID 10373343

4. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats

   Andersen NB, Malmlöf K, Johansen PB, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001

   In 8-month-old female rats treated for 3 months, ipamorelin combined with glucocorticoid increased maximum tetanic tension and periosteal bone formation rate 4-fold compared to glucocorticoid alone.

   Animal study · PMID 11735244

5. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

   Beck DE, Sweeney WB, McCarter MD, et al. · International journal of colorectal disease · 2014

   Multicenter, double-blind, placebo-controlled trial in 117 bowel resection patients. Ipamorelin 0.03 mg/kg IV twice daily for up to 7 days was well tolerated but did not significantly improve postoperative ileus outcomes versus placebo.

   Controlled clinical trial · PMID 25331030